TNFalfa Blocking Treatment of Spondylarthropathies

Conditions

Ankylosing Spondylitis, Psoriatic Arthritis, Spondylarthropathies

Brief summary

The purpose of the study is to establish a Danish cohort of spondylarthropathy (SpA) patients who are being treated with TNFalfa blockers. By following the TNFalfa blocking treated patients the researchers want to identify better biomarkers for disease activity and disease progression. In addition, the researchers want to identify predictors for disease progression.

Pedersen SJ, Sørensen IJ, Garnero P, Johansen JS, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Lambert R, Hansen A, Østergaard M.

2011-05-0886 citations

10.1136/ard.2010.138883

Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.

Pedersen SJ, Sørensen IJ, Hermann KG, Madsen OR, Tvede N, Hansen MS, Thamsborg G, Andersen LS, Majgaard O, Loft AG, Erlendsson J, Asmussen K, Johansen JS, Jurik AG, Møller J, Hasselquist M, Mikkelsen D, Skjødt T, Hansen A, Ostergaard M.

2009-09-0979 citations

10.1136/ard.2009.111187

Interventions

DRUGInfliximab

DRUGEtanercept

DRUGAdalimumab

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Age\>18 years old * Spondylarthropathies according to the European Spondylarthropathy Study Group (ESSG) criteria * Sacroiliitis by X-ray or magnetic resonance imaging (MRI) * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)\>3 * No signs of tuberculosis (TB) * Sufficient contraception

Exclusion criteria

* Wish of pregnancy or nursing * Previous treatment with TNFalfa blocker * Disease-modifying anti-rheumatic drugs (DMARDs) other than methotrexate (MTX) later than 4 weeks before inclusion * Steroid treatment later than 4 weeks before inclusion * Immunosuppressing agents later than 4 weeks before inclusion * Severe infections within 3 months * HIV-infection * Active hepatitis B and C * Active or latent TB * Severe chronic diseases * Heart insufficiency (New York Heart Association \[NYHA\] 3 and 4) * Malignancy * Systemic lupus erythematosus (SLE) or SLE-like disease * Abuse of narcotics or alcohol * Major psychiatric disorders

Countries

Denmark

Outcome results

None listed